Featured Session: Digital Therapeutics for Mental Health – Are We Ready for Prime Time?

Commercially available digital therapeutics (DTx) to treat mental health conditions have been available for over a decade, and the industry has matured substantially. Currently there are dozens of apps for mental health conditions, but only a tiny fraction have chosen to seek regulatory approval and the majority of these are for mental health conditions. In this presentation, we will consider a range of issues pertinent to the growth of the field of DTx for mental health. Using one exemplar product, we will review the parallels between the development of a DTx and the development of a traditional pharmacotherapy, including the steps required for regulatory clearance. We will also explore how DTx currently fits into routine clinical care; and where the “pain points” exist for patients, providers, and payors. Ultimately, we will tackle the question of when DTx are ready to be part of mainstream mental health care.

This presentation is provided by Akili Interactive.